141 related articles for article (PubMed ID: 31218911)
21. N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial.
Schoeps VA; Graves JS; Stern WA; Zhang L; Nourbakhsh B; Mowry EM; Henry RG; Waubant E
Contemp Clin Trials; 2022 Nov; 122():106941. PubMed ID: 36182028
[TBL] [Abstract][Full Text] [Related]
22. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial.
Walsh BT; Kaplan AS; Attia E; Olmsted M; Parides M; Carter JC; Pike KM; Devlin MJ; Woodside B; Roberto CA; Rockert W
JAMA; 2006 Jun; 295(22):2605-12. PubMed ID: 16772623
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D; Mellion M; Hupperts R; Edwards KR; Calabresi PA; Drulović J; Giovannoni G; Hartung HP; Arnold DL; Fisher E; Rudick R; Mi S; Chai Y; Li J; Zhang Y; Cheng W; Xu L; Zhu B; Green SM; Chang I; Deykin A; Sheikh SI;
Lancet Neurol; 2019 Sep; 18(9):845-856. PubMed ID: 31285147
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effects of exercise in people with progressive multiple sclerosis (Exercise PRO-MS): study protocol of a phase II trial.
Gravesteijn AS; Beckerman H; de Jong BA; Hulst HE; de Groot V
BMC Neurol; 2020 May; 20(1):177. PubMed ID: 32393193
[TBL] [Abstract][Full Text] [Related]
25. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
[TBL] [Abstract][Full Text] [Related]
27. Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial.
Lundström E; Isaksson E; Greilert Norin N; Näsman P; Wester P; Mårtensson B; Norrving B; Wallén H; Borg J; Hankey GJ; Hackett ML; Mead GE; Dennis MS; Sunnerhagen KS
Stroke; 2021 Oct; 52(10):3082-3087. PubMed ID: 34465201
[TBL] [Abstract][Full Text] [Related]
28. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.
Kobak KA; Greist JH; Jefferson JW; Katzelnick DJ
J Clin Psychopharmacol; 2002 Jun; 22(3):257-62. PubMed ID: 12006895
[TBL] [Abstract][Full Text] [Related]
29. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial.
Talwalkar JA; Donlinger JJ; Gossard AA; Keach JC; Jorgensen RA; Petz JC; Lindor KD
Dig Dis Sci; 2006 Nov; 51(11):1985-91. PubMed ID: 17053955
[TBL] [Abstract][Full Text] [Related]
30. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
31. Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
Goldstein DJ; Rampey AH; Dornseif BE; Levine LR; Potvin JH; Fludzinski LA
Obes Res; 1993 Mar; 1(2):92-8. PubMed ID: 16350565
[TBL] [Abstract][Full Text] [Related]
32. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
33. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
Marquez-Romero JM; Arauz A; Ruiz-Sandoval JL; Cruz-Estrada Ede L; Huerta-Franco MR; Aguayo-Leytte G; Ruiz-Franco A; Silos H
Trials; 2013 Mar; 14():77. PubMed ID: 23510124
[TBL] [Abstract][Full Text] [Related]
34. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
[TBL] [Abstract][Full Text] [Related]
35. Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.
Rust R; Chien C; Scheel M; Brandt AU; Dörr J; Wuerfel J; Klumbies K; Zimmermann H; Lorenz M; Wernecke KD; Bellmann-Strobl J; Paul F
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33622766
[TBL] [Abstract][Full Text] [Related]
36. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.
Reddihough DS; Marraffa C; Mouti A; O'Sullivan M; Lee KJ; Orsini F; Hazell P; Granich J; Whitehouse AJO; Wray J; Dossetor D; Santosh P; Silove N; Kohn M
JAMA; 2019 Oct; 322(16):1561-1569. PubMed ID: 31638682
[TBL] [Abstract][Full Text] [Related]
37. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
[TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia.
Arnold LM; Hess EV; Hudson JI; Welge JA; Berno SE; Keck PE
Am J Med; 2002 Feb; 112(3):191-7. PubMed ID: 11893345
[TBL] [Abstract][Full Text] [Related]
39. A double-blind trial of four medications to treat severe premenstrual syndrome.
Diegoli MS; da Fonseca AM; Diegoli CA; Pinotti JA
Int J Gynaecol Obstet; 1998 Jul; 62(1):63-7. PubMed ID: 9722128
[TBL] [Abstract][Full Text] [Related]
40. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
